Proteon Therapeutics, Inc. (NASDAQ:PRTO)‘s stock had its “market perform” rating reissued by Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Wednesday.

PRTO has been the topic of a number of other research reports. HC Wainwright set a $2.00 price target on shares of Proteon Therapeutics and gave the company a “hold” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered shares of Proteon Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 17th. Maxim Group set a $6.00 price target on shares of Proteon Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, Cowen and Company reiterated a “hold” rating on shares of Proteon Therapeutics in a report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $8.00.

Proteon Therapeutics (NASDAQ PRTO) traded up 3.85% on Wednesday, reaching $1.35. The company had a trading volume of 912 shares. The stock has a 50 day moving average price of $1.38 and a 200 day moving average price of $1.53. Proteon Therapeutics has a 52-week low of $1.10 and a 52-week high of $11.45. The stock’s market capitalization is $23.79 million.

Proteon Therapeutics (NASDAQ:PRTO) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.11. Analysts expect that Proteon Therapeutics will post ($1.55) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Proteon Therapeutics’ (PRTO) Market Perform Rating Reaffirmed at Oppenheimer Holdings, Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at

An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC bought a new position in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics comprises approximately 0.2% of RA Capital Management LLC’s holdings, making the stock its 22nd largest position. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 41.08% of the company’s stock.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.